Consider an Immunomodulator for Horse Health
How immunomodulators can help decrease upper respiratory disease in horses.
February 27, 2013
From AQHA Corporate Partner Zoetis
Travel, unfamiliar environments, exposure to other horses, breeding and competing are all things that can cause stress to your American Quarter Horses. And often, a stressed horse can lead to a sick horse - particularly upper respiratory disease, caused by equine herpesvirus types 1 and 4 - and add stress
Because many horse industry events feature intermingling of large populations of horses with unknown health status, outbreaks of infectious equine respiratory disease can occur, with major financial implications. Using an immunomodulator can help mitigate the effects of equine upper respiratory disease, particularly in these high-risk settings.
We know you want to keep your horse in the best of health. So we created the AQHA Common Horse Health Issues report gets you steered in the right direction and arms you with the knowledge you need to be a responsible horse owner.
In cases where exposure to equine respiratory pathogens is possible, using an immunomodulator can help boost your horse’s innate immune system. Typically, an adaptive immune system response takes seven to 14 days to produce antibodies against the infectious agent.1-3 But since an immunomodulator activates an innate immune system response - a response that is rapid, short-lived and non-specific - it helps limit the severity of disease until the adaptive immune system has time to target infectious agents.1-3
ZYLEXIS®, an inactivated (killed) Parapox ovis virus, can help stimulate your horse’s immune response prior to these events, aiding in the reduction of equine upper respiratory disease associated with EHV-1 and/or EHV-4 infections. ZYLEXIS is recommended as a course of three single-dose intramuscular injections on days 1, 2 and 9, with the first dose administered shortly before your horse is placed in a stressful situation, such as breeding, traveling, showing or weaning, or during subsequent disease episodes.
Additionally, for the health of your horses, be sure they are current on their vaccinations, whether you are traveling or at home. Vaccines, including WEST-NILE INNOVATOR®, FLUVAC INNOVATOR® and PINNACLE® I.N., are available to help protect your horses against disease. Be sure to consult with your veterinarian before starting any vaccination or immunomodulator program.
You can’t always prevent upper respiratory disease from affecting your horses, but you can help support the immune system by administering an immunomodulator before stressful situations that often cause disease. Because you’ve invested time and money preparing for that big event, don’t let your stressed horse become a sick horse.
In the detailed, downloadable AQHA Common Horse Health Issues report, you'll gain valuable information on disease such as strangles, West Nile virus, equine herpesvirus as well as many other diseases that affect our equine friends.
For more about ZYLEXIS or the Zoetis line of equine vaccines, contact your Zoetis representative, call 888-ZOETIS1 (888-963-8471) or visit https://online.zoetis.com/us/en/products/pages/zylexis.aspx.
We’re Zoetis. Built on 60 years of experience as Pfizer Animal Health, and now focused solely on animal health. FOR ANIMALS. FOR HEALTH. FOR YOU.
1 Mayr A. Development of a non-immunising, paraspecific vaccine from attenuated pox viruses: a new type of vaccine. Microbiologica 2003; 26; 7–12.
2 Weber O, et al. Inactivated parapoxvirus ovis (Orf virus) has antiviral activity against hepatitis B virus and herpes simplex virus. J Gen Virol 2003; 84(Pt 7): 1843–1852.
3 Friebe A, et al. Immunomodulatory effects of inactivated parapoxvirus ovis (Orf virus) on human peripheral immune cells: induction of cytokine secretion in monocytes and Th1-like cells. J Virol 2004; 78(17): 9400–9411.
All trademarks are the property of Zoetis Inc., its affiliates and/or its licensors. All other trademarks are the property of their respective owners. ©2013 Zoetis Inc. All rights reserved.